ASI announces successful completion of $10 million round of financing

NewsGuard 100/100 Score

Access Scientific, Inc. (ASI) today announced the successful completion of a $10 million round of financing. The round was led by CAC and further supported by the company's previous institutional investors.

“The commitment from CAC and our existing investors will allow us to improve the hospital in-patient experience worldwide with this groundbreaking new vascular access technology”

ASI said the funds will be used to facilitate commercialization of the company's transformative new product, The POWERWAND®, through the hiring of a direct sales and clinical force.

"The commitment from CAC and our existing investors will allow us to improve the hospital in-patient experience worldwide with this groundbreaking new vascular access technology," said Steve Bierman, M.D., CEO of Access Scientific. "Recently released clinical trial results on the device prove that many patients can now have one and only one needlestick for vascular access throughout their entire hospitalization. Blood tests can be drawn and fluids/medications administered—all through a single POWERWAND that can last without complications for the length of the patient's stay."

The POWERWAND is an extended-dwell, power-injectable 3.1 inch IV catheter delivered by means of The WAND's® proprietary Accelerated Seldinger Technique.

"Nearly all hospitalized patients today receive IV therapy. Patients' fear of needles is commonly known in healthcare, and the POWERWAND will help reduce the number of needlesticks patients must endure throughout their hospitalization and should positively affect patient satisfaction," said Rod Dammeyer, Managing Director of CAC, a private equity firm headquartered in San Diego, Calif. "The Access Scientific management team has a strong and proven track record in bringing vascular access innovations to market."

Prior to introduction of The POWERWAND, an independent clinical trial conducted by Orlando Regional Medical Center found that patients reported a 58% dissatisfaction rate due to complications and repetitive venipunctures associated with peripheral IV catheters. POWERWAND patients, according to the study, instead rated their satisfaction very highly, at a 9.8 out of 10 satisfaction rating.

In addition to improving the inpatient experience, the new device can help reduce healthcare workers' risk of an accidental, potentially dangerous needlestick.

The POWERWAND is the second WAND product introduced by Access Scientific, Inc. The first is The PICC WAND, currently distributed by both ASI and Teleflex Medical.

Both products enable clinicians to perform the Accelerated Seldinger Technique using the WAND's proprietary all-in-one safety introducer—which is safer, simpler and faster than standard over-wire insertions. The POWERWAND delivers a power-injectable, extended-dwell midline catheter; the PICC WAND delivers a Teleflex peelable sheath introducer for insertion of peripherally inserted central catheters. Access Scientific plans to introduce additional WAND iterations in the near future.

Source:

 Access Scientific

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness